Loomis, Sayles & Company
ABMD

Loomis, Sayles & Company’s Abiomed Inc ABMD Stock Holding History

Loomis, Sayles & Company’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-139
Closed -$34K – 1015
2022
Q3 		$34K Buy
+139
New +$37.5K ﹤0.01% 588
2021
Q2 		– Sell
-43
Closed -$14K – 942
2021
Q1 		$14K Buy
+43
New +$13.8K ﹤0.01% 712
2018
Q2 		– Sell
-21,989
Closed -$6.4M – 937
2018
Q1 		$6.4M Sell
21,989
-9,112
-29% -$2.31M 0.01% 502
2017
Q4 		$5.83M Buy
31,101
+2,507
+9% +$468K 0.01% 512
2017
Q3 		$4.82M Buy
+28,594
New +$4.32M 0.01% 524
2015
Q3 		– Sell
-38
Closed -$2K – 1078
2015
Q2 		$2K Buy
+38
New +$2.52K ﹤0.01% 899

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Loomis, Sayles & Company's ABMD Position: Q4 2022 in Review

Loomis, Sayles & Company sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 139 shares — an estimated $34K sold.

Loomis, Sayles & Company first reported a position in ABMD in Q2 2015 and held it in 6 quarters. The position peaked at $6.4M in Q1 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Loomis, Sayles & Company reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 139 Abiomed Inc shares in Q4 2022, an estimated $34K.
  • Loomis, Sayles & Company first reported a position in Abiomed Inc in Q2 2015 and held it in 6 quarters.
  • Loomis, Sayles & Company's Abiomed Inc position peaked at $6.4M in Q1 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Loomis, Sayles & Company's 13F filing for Q4 2022, filed 10 Feb 2023.